Responsibilities:
- Lead commercial due diligence for external assets (pre-clinical through commercial stage): validate unmet need, target patient/treater populations, competitive landscape, and market access environment.
- Build and own long-term revenue forecasts underpinning deal valuation models; develop planning/upside/downside scenarios based on clinical outcomes, label claims, payer restrictions, competitive dynamics, and commercialization options.
- Execute, commission, and synthesize primary and secondary market research (e.g., KOL interviews, payer boards) to validate clinical value propositions during active deal sprints.
- Develop deal assumptions in collaboration with executive leadership, Market Access, Business Units/Commercial teams, and regional stakeholders.
- Define the strategic thesis for each transaction (the “Why”); assess fit within Oncology portfolio strategies, synergies, and risks.
- Co-develop therapeutic area “areas of interest” with R&D, corporate development/strategy, and commercial leadership; identify market “white space.”
- Pioneer next-generation, tech-forward diligence approaches using advanced predictive analytics.
- Drive change management and adoption of innovative diligence methodologies.
- Create/deliver investment committee and Board presentations; articulate commercial opportunity, risks, and strategic rationale; incorporate leadership feedback.
- Provide objective risk assessments to support leadership Go/No-Go decisions.
Qualifications:
- Bachelor’s degree required; MBA or advanced scientific degree (PhD/MD/PharmD) strongly preferred.
- 15+ years in pharma; at least 10 years in Corporate Development, Business Development, or Strategic Consulting.
- Deep oncology and commercial diligence expertise; proven track record leading commercial diligence (M&A or licensing).
- Advanced deal-valuation forecasting; ability to interpret clinical data and translate into commercial value drivers.
- Proven ability to manage multiple diligence projects under tight timelines.